Age |
Mean (SEM) (SD) | 23 (2) (14) | 28 (2) (17) | 0.03 |
95% CI | 19–25 | 23–32 | |
Sex |
Males | 49 | 44 | NS |
Females | 14 | 10 | |
Duration of seizures (in months) |
Mean (SEM) (SD) | 7 (2) (14) | 19 (5) (38) | 0.02 |
95% CI | 0–21 | 9–29 | |
Prior allergies | 15 | 7 | NS |
Asthma | 4 | 2 | NS |
Drug rash | 13 | 7 | NS |
Helminthiasis | 1 | 1 | NS |
Initial phenytoin treatment |
Intravenous loading | 12 | 11 | NS |
Oral loading | 47 | 35 | |
Oral maintenance | 4 | 8 | |
Baseline hematological parameters |
Total leukocyte count (/mm3) |
Mean (SEM) (SD) | 6601 (266) (2106) | 6870 (294) (2157) | NS |
Range | 3900–15130 | 3800–12900 | |
Absolute eosinophil count (/mm3) |
Mean (SEM) (SD) | 340 (47) (372) | 180 (29) (216) | 0.019 |
Range | 20–2020 | 0–1010 | |
Hematological parameters at 3 weeks |
Total leucocyte count (/mm3) |
Mean (SEM) (SD) | 5303 (349) (2762) | 5471 (3520) (2586) | NS |
Range | 4500–11600 | 4400–12900 | |
Absolute eosinophil count (/mm3) |
Mean (SEM) (SD) | 300 (37) (293) | 164 (36) (264) | 0.024 |
Range | 20–1700 | 0–1400 | |